CoChat

The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status

Open access
Li, Lan, Cong, Cong, Zhang, Xiaolan, Zhang, Xiaoxia · 2026 · Diabetes, Metabolic Syndrome and Obesity

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 14 of the 38 sources its claims cite were checked for support.

Abstract

Background: The rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates effective therapies. This meta-analysis therefore assesses the efficacy of omega-3 PUFAs in reducing triglycerides in MASLD patients and examines how diabetes status modulates this effect. Purpose: To resolve existing uncertainties, this systematic review and meta-analysis was conducted to evaluate the efficacy of omega-3 PUFAs in reducing TG among MASLD patients, with a prespecified analysis to elucidate the role of diabetes status. Patients and Methods: We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library (up to Sep 22, 2025) for randomized controlled trials assessing omega-3 PUFA supplementation on triglyceride levels in MASLD patients, with subgroup analysis by diabetes status. Results: Pooled data from 9 studies (n=528) revealed that omega-3 PUFA supplementation was associated with a significant reduction in triglyceride (TG) levels in MASLD patients (MD: -13.81 mg/dL; 95% CI: -24.56, -3.06); however, considerable heterogeneity (I²=22.5%) suggests that the true effect may be inconsistent across different patient populations. Subgroup analysis delineated a stark contrast: while a beneficial effect was confirmed in non-diabetic MASLD patients (MD: -15.78 mg/dL), it was absent in those with comorbid type 2 diabetes (P = 0.33). Meta-regression further confirmed that the prevalence of diabetes within study populations did not linearly influence the TG-lowering outcome (P = 0.752). Finally, the intervention showed no significant impact on other metabolic parameters such as ALT, HDL, or LDL. Conclusion: This meta-analysis suggests that omega-3 fatty acids are associated with reduced TG levels in MASLD patients on average, but the effect is inconsistent and influenced by diabetes status. The non-significant effect in diabetic patients and the wide prediction intervals call for caution in interpreting these findings, and further research is needed to identify subgroups that may benefit.

Overview

CoChat Summary

## TL;DR

This meta-analysis of 9 randomized controlled trials (n=528) found that omega-3 PUFA supplementation was associated with a modest reduction in triglycerides in patients with MASLD overall (MD −13.81 mg/dL). The benefit was seen in non-diabetic patients but not in patients with type 2 diabetes, and no significant effects were found for ALT, HDL, or LDL.

## Key findings

  • Across 9 RCTs including 528 participants, omega-3 supplementation reduced triglycerides in MASLD overall by MD −13.81 mg/dL (95% CI −24.56 to −3.06), with I² = 22.5%.
  • In the non-diabetic subgroup (4 studies, n=214), triglycerides decreased by MD −15.78 mg/dL (95% CI −27.25 to −4.31).
  • In the diabetic subgroup (2 studies, n=97), the triglyceride effect was not significant (MD −16.71 mg/dL, 95% CI −50.28 to 16.85; P = 0.33).
  • Meta-regression found that the proportion of diabetic patients did not explain heterogeneity in triglyceride response (regression coefficient = 15.703; P = 0.752; R² ≈ 0%).
  • Omega-3 had no significant impact on other metabolic indicators: ALT (7 studies, 428 participants; MD −1.44 IU/L), HDL (7 studies, 454 participants; MD −0.06 mg/dL), or LDL (7 studies, 452 participants; MD 0.26 mg/dL).

## Methods

  • Systematic review and meta-analysis of randomized controlled trials of omega-3 PUFA supplementation in adult MASLD patients, with prespecified subgroup analysis by diabetes status.
  • Searched PubMed, Web of Science, Embase, and the Cochrane Library through September 22, 2025; the review followed PRISMA and was registered in PROSPERO (CRD420251160035).
  • Primary analysis used random-effects meta-analysis of mean differences (MDs) with 95% CIs; heterogeneity was assessed with I² and Cochran’s Q, and meta-regression tested whether diabetes prevalence modified the effect.

## Limitations

  • The paper states that the number of included studies was limited, especially in the diabetes subgroup, which may have reduced statistical power.
  • The paper states there was heterogeneity across studies in omega-3 dosage, treatment duration, and patient characteristics, leaving possible residual confounding despite random-effects modeling and meta-regression.
  • The paper states that outcomes were mainly laboratory markers rather than clinical endpoints such as liver fibrosis progression or cardiovascular events, so long-term benefits remain uncertain.
  • Evident from the text: the diabetic subgroup was very small (2 studies, n=97), and the review did not assess publication bias because the number of studies was too limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/dmso.s573711

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flowchart of the study selection process for the systematic review and meta-analysis.
Figure 1 Flowchart of the study selection process for the systematic review and meta-analysis.CC BY-NC · PubMed Central
Figure 2 Risk of bias summary for the included randomized controlled trials.
Figure 2 Risk of bias summary for the included randomized controlled trials.CC BY-NC · PubMed Central
Figure 3 Forest plot for the effect of omega-3 supplementation on triglyceride levels in patients with MASLD. The 95% prediction interval is shown, indicating the expected range of true effects in future study settings.
Figure 3 Forest plot for the effect of omega-3 supplementation on triglyceride levels in patients with MASLD. The 95% prediction interval is shown, indicating the expected range of true effects in future study settings.CC BY-NC · PubMed Central
Figure 4 Forest plot of subgroup analysis based on diabetic status for the effect of omega-3 supplementation on triglyceride levels. Subgroups: (A) patients with MASLD without diabetes; (B) patients with MASLD and concomitant diabetes.
Figure 4 Forest plot of subgroup analysis based on diabetic status for the effect of omega-3 supplementation on triglyceride levels. Subgroups: (A) patients with MASLD without diabetes; (B) patients with MASLD and concomitant diabetes.CC BY-NC · PubMed Central
Figure 5 Meta-regression bubble plot evaluating the association between the proportion of participants with diabetes and the effect size (mean difference in triglyceride levels). The size of the bubbles corresponds to the weight of each study in the analysis.
Figure 5 Meta-regression bubble plot evaluating the association between the proportion of participants with diabetes and the effect size (mean difference in triglyceride levels). The size of the bubbles corresponds to the weight of each study in the analysis.CC BY-NC · PubMed Central
Figure 6 Forest plots for the effects of omega-3 supplementation on secondary outcomes. (A) alanine aminotransferase (ALT) levels; (B) high-density lipoprotein (HDL) cholesterol levels; (C) low-density lipoprotein (LDL) cholesterol levels.
Figure 6 Forest plots for the effects of omega-3 supplementation on secondary outcomes. (A) alanine aminotransferase (ALT) levels; (B) high-density lipoprotein (HDL) cholesterol levels; (C) low-density lipoprotein (LDL) cholesterol levels.CC BY-NC · PubMed Central

Verification

Claims the paper makes

11 Valid · 2 Not valid · 9 Not checked · 23 Own results and interpretations

18 more claims · 1 with their cited sources checked

Create a free account to see all 45 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 1

  1. Tetri, 2008, Am J Physiol Gastr Liver Physiol, 295, G987

Metadata

Authors
Li, L., Cong, C., Zhang, X., & Zhang, X.
Affiliations
Shandong University of Traditional Chinese Medicine (CN)
Corresponding author
Zhang, Xiaoxia
ORCID
Li, Lan
Venue
Diabetes, Metabolic Syndrome and Obesity
Published
2026-01
Volume
Volume 19
Pages
1-14
ISSN
1178-7007 (ISSN-L)
OpenAlex
W7125436140
Cited by
0
References
50
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
omega-3 fatty acids, polyunsaturated fatty acids, triglycerides, non-alcoholic fatty liver disease, type 2 diabetes, triglyceride lowering, dietary supplementation, subgroup analysis, ALT, HDL cholesterol, LDL cholesterol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.